Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arwed Cleve

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Molecular and Cellular Endocrinology|June 28, 2011
Recent developments in antiandrogens and selective androgen receptor modulatorsBernard Haendler, Arwed Cleve
Chemmedchem|August 24, 2016
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876Holger Siebeneicher, Arwed Cleve, Hartmut Rehwinkel, et al.
Chemmedchem|November 9, 2018
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic TherapiesCarsten Möller, Wilhelm Bone, Arwed Cleve, et al.
Oncotarget|January 14, 2016
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsTatsuo Sugawara, Pascale Lejeune, Silke Köhr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Molecular and Cellular Endocrinology|June 28, 2011
Recent developments in antiandrogens and selective androgen receptor modulatorsBernard Haendler, Arwed Cleve
Chemmedchem|August 24, 2016
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876Holger Siebeneicher, Arwed Cleve, Hartmut Rehwinkel, et al.
Chemmedchem|November 9, 2018
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic TherapiesCarsten Möller, Wilhelm Bone, Arwed Cleve, et al.
Oncotarget|January 14, 2016
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsTatsuo Sugawara, Pascale Lejeune, Silke Köhr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Pageof 1